Current studentsExisting staffContact us
 

Detection of Adverse Medicine Events by Pharmacists in Residential Aged Care Facilities: secondary Analysis of Data From ReMInDAR Trial

Simple item page
dc.contributor.authorMekuria, A.B.
dc.contributor.authorLim, R.
dc.contributor.authorAndrade, A.Q.
dc.contributor.authorRowett, D.
dc.contributor.authorRoughead, E.E.
dc.date.issued2025
dc.description.abstractBackground: Pharmacists often identify symptoms during medication reviews that may or may not be adverse medicine events (AMEs), but these have not yet been quantified. This study aimed to quantify the extent of these symptoms representing AMEs by comparing them with a known set of AMEs and symptoms listed in existing medicine-related symptom assessment tools. Method: A secondary analysis of data from the Reducing Medicine-Induced Deterioration and Adverse Reactions (ReMInDAR) trial was conducted. Adverse events or symptoms were extracted from pharmacists' progress notes, and their frequency and Medicine Likeliness Ratio (probability of being medicine-related) were determined. Pharmacist-recorded adverse events were compared to a subset of AMEs identified by a clinical panel, and agreement was assessed using Cohen's κ. Pharmacist-recorded adverse events or symptoms were also compared with those in the PHArmacotherapeutical Symptom Evaluation-20 questions (PHASE-20), and the Patient Reported Outcome Measure, Inquiry into Side Effects (PROMISE). Result: Pharmacists recorded 3.1 symptoms per person; 68.8% of the symptoms had a medicine-likeness ratio ≥ 40.0%. The most prevalent medicine-related events recorded by pharmacists included falls (13.6%), swelling (7.1%), constipation (5.4%), nocturia (4.2%), shortness of breath (4.0%), bleeding (4.0%), nausea and vomiting (3.1%), dizziness (2.8%), drowsiness (2.3%), and rash (2.0%). Of the subset of 273 AMEs identified by the panel, 14.7% corresponded to adverse events recorded by pharmacists. The agreement between pharmacist-recorded and panel-identified AMEs was significant but low (κ = 0.074, p = 0.008). The majority of frequently detected medicine-related symptoms were in PROMISE (56.4% of recorded AMEs) and PHASE-20 (81.3% of recorded AMEs). Conclusion: While pharmacists recorded a notable number and variety of adverse events or symptoms, underreporting and discrepancies were still observed. As items in the PHASE-20 aligned with most recorded events, further research is warranted to determine if it can help pharmacists in improving the detection and monitoring of AMEs.
dc.identifier.citationPharmacoepidemiology and Drug Safety, 2025; 34(11, article no. e70261):1-9
dc.identifier.doi10.1002/pds.70261
dc.identifier.issn1053-8569
dc.identifier.issn1099-1557
dc.identifier.urihttps://hdl.handle.net/11541.2/45409
dc.language.isoen
dc.publisherJohn Wiley & Sons
dc.relation.fundingAustralian Government Department of Health Pharmacy Trial Program
dc.rightsCopyright 2025 The author(s) (https://creativecommons.org/licenses/by/4.0/) Access Condition Notes: This is an open access article
dc.source.urihttps://doi.org/10.1002/pds.70261
dc.subjectadverse medicine events
dc.subjectmedication review
dc.subjectmedication safety
dc.subjectolder people
dc.subjectpatient reported outcomes
dc.subjectpharmacy services
dc.titleDetection of Adverse Medicine Events by Pharmacists in Residential Aged Care Facilities: secondary Analysis of Data From ReMInDAR Trial
dc.typeJournal article
pubs.publication-statusPublished
ror.fileinfo12309666970001831 13309666960001831 Open Access Published Version
ror.mmsid9917087551301831

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
9917087551301831_12309666970001831_Detection of Adverse Medicine.pdf
Size:
213.58 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections